-1753361001450.webp&w=3840&q=75)
2025 NOSCM | What is New in EGFR and ALK NSCLC?
0% Complete
Course Overview
Dr. Julia Rotow updated on EGFR and ALK mutations, stressing the use of osimertinib and lorlatinib.
Course Content
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Objectives
NA
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Julia Rotow, MD
Disclosure
<p>NA</p>
Accreditation
NA
-1773064915543.webp&w=3840&q=75)
-1773064818174.webp&w=3840&q=75)